Source Fact: Financial Supervisory Service DART / 2024-11-18
Disclosure Type: Conclusion of Single Sales/Supply Contract (Amendment)
💡 3-Second Summary
Samsung Biologics has revised its existing contract manufacturing organization (CMO) agreement with global pharmaceutical giant Roche, increasing the total contract value to approximately KRW 241.4 billion and extending the duration by one year until the end of 2028 upon the client’s request.
📊 1. [Summary of Core Disclosure & Key Figures]
- Amended Original Disclosure: Single Sales/Supply Contract initially submitted on January 15, 2021
- Contract Name: Contract Manufacturing Agreement (Drug Substance Manufacturing)
- Counterparty: F.Hoffmann-La Roche Ltd (Roche)
- Changes in Contract Amount:
- Pre-amendment: KRW 234,432,963,608 (USD 213,062,767.98)
- Post-amendment: KRW 241,384,246,418 (USD 219,380,393)
- Net Increase: An increase of approx. KRW 6.95 billion (USD 6,317,625 added)
- Applied FX Rate: Fixed at KRW 1,100.30 per USD (The standard proxy rate on the initial disclosure date of January 15, 2021)
- Ratio to Revenue: Increased from 33.41% to 34.41% relative to the revenue baseline at the time of initial disclosure (KRW 701.59B)
- Changes in Contract Period:
- Pre-amendment: June 1, 2020 ~ December 31, 2027
- Post-amendment: June 1, 2020 ~ December 31, 2028 (Extended by 1 year)
📈 2. [Expert Insight: Implications for Investors]
- Strengthened Partnership & Fundamental Validation: The upward revision and extension of a contract with an elite global pharmaceutical peer like Roche reflects the client’s high trust in Samsung Biologics’ manufacturing quality and timeline execution. This serves as a solid Fundamental indicator enhancing mid-to-long-term corporate stability.
- Sustained Order Backlog Expansion: This amendment adds roughly KRW 6.95 billion to the locked-in order book. As the contract expiration is deferred to late 2028, it could potentially secure longer visibility for plant utilization and long-term cash flow generation from this specific client.
- Investor Consideration: Market participants should note that the KRW amounts displayed in this filing are calculated based on the historical FX rate from January 2021 (KRW 1,100.30/$). Consequently, the actual revenue recognized in the future may vary from the disclosed figures depending on the real-time USD/KRW conversion rates at the time of invoicing and delivery.
📝 Editor’s Comment (by K-STOCK Editor)
An upward revision and extension of an existing contract is one of the healthiest signals in the biopharma CMO market. This filing indicates that top-tier big pharma Roche has requested incremental capacity from Samsung Biologics, confirming a robust lock-in effect by shifting the contract runway out through 2028. While the net addition of roughly KRW 6.95 billion is relatively modest compared to Samsung Biologics’ current massive annual revenue scale, the structural takeaway is highly encouraging. It demonstrates that strategic ties with anchor clients remain deep and expanding, offering reassuring long-term visibility to shareholders.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
